NASDAQ:PRAN

Alterity Therapeutics (PRAN) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$1.90
$2.10
50-Day Range
$0.95
$2.06
52-Week Range
$1.09
$2.91
Volume
44,669 shs
Average Volume
130,956 shs
Market Capitalization
$17.80 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
PRAN stock logo

About Alterity Therapeutics Stock (NASDAQ:PRAN)

Alterity Therapeutics Ltd. engages in the development of therapeutic drugs designed to treat the underlying causes of degeneration of the brain as the aging process progresses. It focuses on Parkinson's movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company was founded by Geoffrey Paul Kempler on November 11, 1997 and is headquartered in Melbourne, Australia.

PRAN Stock News Headlines

Kazia Therapeutics Limited (KZIA)
READ THIS – If You Missed Out On The AI Boom
Adam’s research shows a radical new technology is set to grow 10X faster than the internet … and drastically alter manufacturing, healthcare, agriculture … even energy. Nvidia’s CEO said it will be, “flat out, the biggest [tech] revolution ever.”
Alterity Therapeutics Appoints Phillip Hains as Chief Financial Officer
Why Is Alterity Therapeutics (ATHE) Stock Up 150% Today?
Axsome Therapeutics Inc AXSM
ADRs End Higher; Orchard Therapeutics PLC Climbs 96%
READ THIS – If You Missed Out On The AI Boom
Adam’s research shows a radical new technology is set to grow 10X faster than the internet … and drastically alter manufacturing, healthcare, agriculture … even energy. Nvidia’s CEO said it will be, “flat out, the biggest [tech] revolution ever.”
See More Headlines
Receive PRAN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alterity Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:PRAN
Fax
N/A
Employees
14
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$150,000.00
Book Value
$1.40 per share

Miscellaneous

Free Float
N/A
Market Cap
$17.80 million
Optionable
Not Optionable
Beta
1.05
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Geoffrey Paul Kempler
    Executive Chairman & Chief Executive Officer
  • Kathryn J. E. Andrews
    Chief Financial Officer
  • David A. Stamler
    Chief Medical Officer & SVP-Clinical Development
  • Phillip Allen Hains
    Secretary

PRAN Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Alterity Therapeutics own?
This page (NASDAQ:PRAN) was last updated on 5/10/2024 by MarketBeat.com Staff

From Our Partners